CLINICAL AND BIOLOGICAL EVALUATION OF THE NOVEL CD30/CD16A TETRAVALENT BISPECIFIC ANTIBODY (AFM13) IN RELAPSED OR REFRACTORY CD30‐POSITIVE LYMPHOMA WITH CUTANEOUS PRESENTATION: A BIOMARKER PHASE IB/IIA STUDY (NCT03192202). (12th June 2019) - Sawas, A.; Chen, P.; Vlad, G.; Lipschitz, M.; Abdul‐Hay, M.; Lue, J.; Deng, C.; Amengual, J.E.; Marchi, E.; Shulman, J.; Elgedawe, H.; Shong, M.V.; et al.